C

CHU de Liege | CHR Citadel - Department of Gyneacology and Obstetrics

Research site
(Unclaimed)
Location
Boulevard du 12 eme de Ligne,1, Liege, Liege, Belgium
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

16 of 39
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Enrolling
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Enrolling
Colitis, Ulcerative
Drug: Placebo
Biological: Golimumab

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose e...

Enrolling
Relapsed or Refractory Multiple Myeloma
Previously Treated Amyloid Light-chain (AL) Amyloidosis
Drug: JNJ-79635322
Locations recently updated

The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not...

Enrolling
Melanoma
Drug: Nivolumab + Relatlimab
Drug: rHuPH20

The study consists of 4 sub-studies, as follows:Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety...

Active, not recruiting
Crohn's Disease
Drug: Risankizumab SC
Drug: Risankizumab On-Body Injector (OBI)

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specifi...

Enrolling
HER2-positive Breast Cancer
Drug: T-DM1
Drug: placebo

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: risankizumab
Drug: placebo for risankizumab

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Locations recently updated

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

Active, not recruiting
Crohn's Disease (CD)
Drug: ABT-494

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The...

Active, not recruiting
Uterine Cervical Neoplasms
Uterine Neoplasms
Drug: fulvestrant
Drug: trastuzumab

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankiz...

Active, not recruiting
Crohn's Disease (CD)
Drug: Ustekinumab
Drug: Risankizumab

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting
Prostate Cancer
Drug: Placebo plus enzalutamide
Drug: talazoparib plus enzalutamide

Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21.Ph...

Active, not recruiting
Follicular Lymphoma
DLBCL
Drug: Vincristine
Drug: Tazemetostat

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for teliso...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cer...

Enrolling
Cervical Cancer
Drug: tisotumab vedotin
Drug: gemcitabine

Trial conditions

Crohn Disease (8 trials)
Lymphoma (7 trials)
Colitis (5 trials)
Ulcer (5 trials)
Ulcerative Colitis (5 trials)
Breast Cancer (3 trials)
Non-Small-Cell Lung Carc... (3 trials)
Atopic Dermatitis (2 trials)
Dermatitis (2 trials)
Eczema (2 trials)

And 31 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems